WEBDec 18, 2019 · In patients with advanced ovarian cancer receiving first-line standard therapy including bevacizumab, the addition of maintenance olaparib provided a significant progression-free survival...
DA:78PA:6MOZ Rank:14
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian
WEBOct 21, 2018 · The use of maintenance therapy with olaparib provided a substantial benefit with regard to progression-free survival among women with newly diagnosed advanced ovarian cancer and a BRCA1/2...
DA:38PA:96MOZ Rank:81
Role of Olaparib as Maintenance Treatment for Ovarian Cancer: …
WEBDec 27, 2019 · Olaparib is a PARP inhibitor that has been approved for maintenance for BRCA-mutated ovarian cancer in the recurrent and front-line setting as well as for treatment of BRCA-mutated ovarian cancer in patients who have received multiple prior lines of chemotherapy.
DA:93PA:28MOZ Rank:99
Maintenance olaparib for patients with newly diagnosed advanced ovarian
WEBOct 26, 2021 · Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology. Articles | Volume 22, ISSUE 12, P1721-1731, December 2021.
DA:1PA:31MOZ Rank:48
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
WEBMay 19, 2023 · The first-line setting in advanced ovarian cancer represents a key opportunity for cure, so it is noteworthy that, in PAOLA-1, with a median duration of follow-up for OS of 61.7 months, updated PFS analysis in patients with HRD-positive tumors at the current data cut-off showed a 59% reduction in risk of disease progression or death with …
DA:35PA:67MOZ Rank:45
Final overall survival (OS) results from SOLO2/ENGOT-ov21: A …
WEBFinal overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. | Journal of Clinical Oncology. …
DA:1PA:12MOZ Rank:48
Overall Survival With Maintenance Olaparib at a 7-Year Follow …
WEBSep 9, 2022 · Results indicate a clinically meaningful, albeit not statistically significant according to prespecified criteria, improvement in OS with maintenance olaparib in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation and support the use of maintenance olaparib to achieve long-term remission in this setting; the potential for c...
DA:26PA:24MOZ Rank:85
Maintenance olaparib for patients with newly diagnosed advanced ovarian
WEBMaintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021 Dec;22 (12):1721-1731. doi: 10.1016/S1470-2045 (21)00531-3. Epub 2021 Oct 26. Authors.
DA:3PA:40MOZ Rank:85
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
WEBDec 19, 2019 · Conclusions: In patients with advanced ovarian cancer receiving first-line standard therapy including bevacizumab, the addition of maintenance olaparib provided a significant progression-free survival benefit, which was substantial in patients with HRD-positive tumors, including those without a BRCA mutation.
